Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 50 of 97, showing 5 Applications out of 482 total, starting on record 246, ending on 250

# Protocol No Study Title Investigator(s) & Site(s)

246.

ECCT/13/04/08  
    Switching At Low HIV-1 RNA Into Fixed Dose Combinations   SALIF   Protocol Number: TMC278IFD3002 Amendment INT-1   
Principal Investigator(s)
1. Edwin Onyango WERE
2. Milton Tony OMONDI
3. Gina OUATTARA
4. Gaudensia Nzembi MUTUA
5. Reena SHAH
Site(s) in Kenya
1. Aga Khan University Hospital (Nairobi City county)
2. KEMRI/Walter-Reed Project Kombewa (Kisumu county)
3. Partners in Prevention (Uasin Gishu county)
4. Kenya AIDS Vaccine Initiative - KNH (Nairobi City county)
5. Kenya AIDS Vaccine Initiative - Kangemi (Nairobi City county)
 
View

247.

ECCT/20/04/02   PROSYNK Study
    A 4-arm, open-label, individually randomized, controlled, phase-2, study of a probiotic and two synbiotics in young children in western Kenya.   
Principal Investigator(s)
1. Stephen Allen
Site(s) in Kenya
1. Homa Bay County Referral Hospital (Homa Bay county)
2. Siaya County Referral Hospital (Siaya county)
3. Migori County Referral Hospital (Migori county)
4. Rongo Sub-County Hospital (Migori county)
5. Rachuonyo Sub County Hospital (Homa Bay county)
6. Kendu Bay Sub-County Hospital (Homa Bay county)
7. Ahero County Hospital (Kisumu county)
8. Rabuor Sub-County Hospital (Kisumu county)
9. Akala Sub-County Hospital (Siaya county)
10. Bondo Sub-County Hospital (Siaya county)
 
View

248.

ECCT/17/03/01   The POWER cohort
    A cohort for evaluation of open-label PrEP delivery among Kenyan and South African women   
Principal Investigator(s)
1. Dr. Stella Njuguna
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital. (Kisumu county)
 
View

249.

ECCT/22/08/02   AIM-LVRNA009-II_III-01
    A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde   
Principal Investigator(s)
1. Bernhards Ogutu
2. Lucas Otieno
3. Videlis Nduba
4. Bernhards Ogutu
5. Jacqueline Mirera
6. Jacqueline Mirera
Site(s) in Kenya
1. Siaya Clinical Trials Unit (Siaya county)
2. Homa Bay Clinical Trials Unit (Homa Bay county)
3. Ahero Clinical Trials Unit (Kisumu county)
4. CREA-N Machakos (Machakos county)
5. CREA-N Nakuru (Nakuru county)
6. Victoria Biomedical Research Institue (Kisumu county)
 
View

250.

ECCT/21/03/01   Recombinant COVID-19 vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older   
Principal Investigator(s)
1. Walter Jaoko Jaoko
Site(s) in Kenya
KAVI-institute of Clinical Research
 
View